Alvogen Korea clinical trials

Acquired by Lotus Pharmaceutical Co., Ltd.

The registry lists 24 studies whose lead sponsor is Alvogen Korea. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 2, 2026.

Studies

Recruiting first, then most recently updated. Showing 24 of 24. All Lotus Pharmaceutical Co., Ltd. studies →

• A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHDNot yet recruitingNCT07678827Phase 3

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• Phase IV Study of Qsymia in Obese PatientsCompletedNCT05378503Phase 4

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• AK-R215 Pharmacokinetic Study Phase IStatus unknownNCT03321318Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• DP-R213 Phase 1 Pharmacokinetics StudyCompletedNCT03010267Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• Clinical Trial to Evaluate the Efficacy and Safety of DP-R212WithdrawnNCT02955368Phase 3

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• A Phase 1 Drug Drug Interaction Clinical Trial of C1-R215 and C2-R215 in Healthy Male VolunteersStatus unknownNCT03005340Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each MonotherapyCompletedNCT02770261Phase 3

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With OsteoporosisCompletedNCT01581320Phase 3

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive DiseaseCompletedNCT02393612Phase 3

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• Safety and Pharmacokinetic Characteristics of DP-R206(Vitamin D3) in Healthy Adult VolunteersCompletedNCT01577849Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• DP-R213 Pharmacokinetics StudyCompletedNCT02762643Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• Safety and Pharmacokinetic Characteristics of DP-R206 in Healthy Adult VolunteersCompletedNCT01429675Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• DP-R212 Pharmacokinetic Study Phase IStatus unknownNCT02814500Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• DP-R208 Pharmacokinetic StudyCompletedNCT02709187Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• DP-R212 Pharmacokinetic StudyStatus unknownNCT02789475Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• A Study to Compare the Pharmacokinetics of DP-R207 in Comparison to Each Component Administered AloneCompletedNCT02730689Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace TabletsCompletedNCT02718846Phase 4

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• Clinical Trial to Compare the Pharmacokinetics of DP-R208CompletedNCT02707224Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• A Drug-drug Interaction Study of DP-R213CompletedNCT02654093Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary HypercholesterolemiaCompletedNCT02445352Phase 3

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• Pharmacokinetic Drug Interaction Between Candesartan and RosuvastatinCompletedNCT02079506Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• Pharmacokinetic / Pharmacodynamic (PK/PD) Study of Multiple Doses of DP-R202 in Healthy VolunteersCompletedNCT01429688Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• Bioavailability Study of DP-R202 in Healthy Male Volunteers Under Fed ConditionsCompletedNCT01421576Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group

• Safety and Pharmacokinetic Characteristics of DP-R202 in Healthy Male VolunteersCompletedNCT01421563Phase 1

  Sponsor listed in the registry: Alvogen Korea · Alvogen Korea — acquired company within the Lotus Pharmaceutical Co., Ltd. group